Therapeutic research for osteoporosis with rheumatoid arthritis

骨质疏松症合并类风湿性关节炎的治疗研究

基本信息

项目摘要

Objective. Periarticular osteoporosis and joint destruction are major complications in rheumatoid arthritis (RA), caused by osteoclast-mediated bone resorption. However, the mechanisms of monocyte osteoclast maturation and role of rheumatoid arthritis endothelial cells (RAEC) in the control of osteoclastogenesis remain unclear. The present study was designed to determine the most important factors that influence monocyte accumulation and osteoclast formation among the many factors produced by RAEC.Methods. We analyzed the expression profiles of various genes in human endothelial cells from various organs (RA synovium, umbilical vein, skin, liver sinusoid, renal glomerulus and brain) using oligonucleotide microarrays. The microarray data were assessed by real-time quantitative polymerase chain reaction, enzyme-linked immunosorbent assay, and immunostaining of RA synovia. Migration of monocytes was assessed by the chemotactic chamber EZ-TAXIScanTM. Tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cell formation was observed by microscopy.Results. Among many epithelial-expressed factors, macrophage-colony stimulating factor (M-CSF) gene was abundantly expressed specifically in RAEC. Fibroblast growth factor-2 (FGF-2) gene was also overexpressed on RAEC. Migration of monocytes and osteoclast formation in co-cultures promoted by culture supernatants of RAEC were inhibited by M-CSF neutralizing antibody.Conclusion. M-CSF produced by RAEC is involved in osteoclastogenesis from monocytes ; migration, and TRAP-positive multi-nuclear cell formation, resulting in joint destruction of RA.
Objective.类风湿关节炎(RA)的主要并发症是关节周围骨质疏松和关节破坏,由破骨细胞介导的骨吸收引起。然而,单核细胞破骨细胞成熟的机制和类风湿关节炎内皮细胞(RAEC)在控制破骨细胞生成中的作用仍不清楚。本研究旨在确定RAEC产生的众多因素中影响单核细胞积聚和破骨细胞形成的最重要因素。方法。我们使用寡核苷酸微阵列分析了来自各种器官(RA滑膜、脐静脉、皮肤、肝窦、肾小球和脑)的人内皮细胞中各种基因的表达谱。微阵列数据通过实时定量聚合酶链反应、酶联免疫吸附试验和RA滑膜免疫染色进行评估。通过趋化室EZ-TAXIScanTM评估单核细胞的迁移。抗酒石酸酸性磷酸酶(TRAP)阳性多核细胞的形成通过显微镜观察。巨噬细胞集落刺激因子(macrophage-colony stimulating factor,M-CSF)基因在RAEC中特异性表达。成纤维细胞生长因子-2(FGF-2)基因在RAEC上也有过表达。M-CSF中和抗体可抑制RAEC培养上清促进的单核细胞迁移和破骨细胞形成。由RAEC产生的M-CSF参与单核细胞的破骨细胞生成、迁移和TRAP阳性多核细胞形成,导致RA的关节破坏。

项目成果

期刊论文数量(38)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
岡田洋右, 田中良哉: "抗炎症治療の滑膜病変に対する効果"腎と骨代謝. 16. 51-57 (2003)
Hiroaki Okada、Yoshiya Tanaka:“抗炎治疗对滑膜病变的影响”《肾脏和骨代谢》16. 51-57 (2003)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Y.Okada, A.Montero, X.Zhang, et al.: "Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone."J Biol Chem. 278. 21258-21266 (2003)
Y.Okada、A.Montero、X.Zhang 等人:“Fgf2 缺失小鼠骨髓培养物中破骨细胞形成对甲状旁腺激素的反应受损。”J Biol Chem。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Fibroblast growth factor-2 induces receptor activator of nuclear factor kappa B ligand expression and osteoclast maturation by binding to heparin sulfate proteoglycan on rheumatoid synovial fibroblasts.
成纤维细胞生长因子 2 通过与类风湿滑膜成纤维细胞上的硫酸肝素蛋白聚糖结合,诱导核因子 kappa B 受体激活剂配体表达和破骨细胞成熟。
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Nakano K;et al.
  • 通讯作者:
    et al.
Y.Okada, C.Pilbeam, L.Raisz, Y.Tanaka: "Role of cyclooxygenase-2 in bone resorption."J UOEH. 25. 185-195 (2003)
Y.Okada、C.Pilbeam、L.Raisz、Y.Tanaka:“环氧合酶 2 在骨吸收中的作用。”J UOEH。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Y.Tanaka, Y.Okada, T.Nakamura: "Inter- and infra-cellular signaling in secondary osteoporosis."J Bone Miner Metab. 21. 61-66 (2003)
Y.Tanaka、Y.Okada、T.Nakamura:“继发性骨质疏松症中的细胞间和细胞内信号传导。”J Bone Miner Metab。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OKADA Yosuke其他文献

OKADA Yosuke的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OKADA Yosuke', 18)}}的其他基金

Comprehensive Studies on Competition Policy and Digital Economy
竞争政策与数字经济综合研究
  • 批准号:
    18H00847
  • 财政年份:
    2018
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Economic Impact of the Antimonopoly Law: Case Studies in Recent Court and Tribunal Decisions
反垄断法的经济影响:近期法院和法庭裁决的案例研究
  • 批准号:
    24330084
  • 财政年份:
    2012
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic research for osteoporosis with rheumatoid arthritis
骨质疏松症合并类风湿性关节炎的治疗研究
  • 批准号:
    18591129
  • 财政年份:
    2006
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of cyclooxygenase-2 in bone metabolism -analysis of cox-2 konckout mice-
环氧合酶-2在骨代谢中的作用-cox-2敲除小鼠的分析-
  • 批准号:
    13671168
  • 财政年份:
    2001
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Research Grant
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
    Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
  • 批准号:
    10733789
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Microbial metabolites impacting the response to methotrexate in rheumatoid arthritis
微生物代谢物影响类风湿性关节炎对甲氨蝶呤的反应
  • 批准号:
    10578433
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
一种有效的 TNFα D 肽抑制剂,用于治疗类风湿性关节炎
  • 批准号:
    10822182
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
Fibroblast-mediated inflammatory resolution of rheumatoid arthritis
成纤维细胞介导的类风湿性关节炎炎症消退
  • 批准号:
    10604629
  • 财政年份:
    2023
  • 资助金额:
    $ 2.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了